AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
VJHemOnc Podcast
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
Mar 15, 2024
Dr. Maria-Victoria Mateos discusses the impact of CAR-T therapy in myeloma, patient selection, and the evolving role of autoSCT. They explore the significance of CAR-T therapy in earlier treatment lines and optimizing outcomes through patient selection and therapeutic sequencing.
13:01
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- CAR-T therapy has revolutionized myeloma treatment with approved cells like ide-cel and cilta-cel.
- Optimizing CAR-T outcomes requires careful patient selection and bridging therapy to manage toxicity effectively.
Deep dives
Impact of CAR-T Therapy on Myeloma Treatment Landscape
CAR-T therapy has significantly impacted the myeloma treatment landscape, with novel compounds improving overall survival in multiple myeloma patients. The introduction of BCMA CAR-T treatments, such as ID cell and Finta cell, has shown effectiveness in relapsed refractory myeloma. These treatments have demonstrated superiority in clinical studies, indicating the potential for earlier implementation of CAR-T therapy to enhance patient outcomes.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode